Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid.
Department of Gastroenterology, Endocrinology, Metabolism and Infectiology, University of Marburg, Baldinger Strasse, D-35043 Marburg, Germany.
Patrick
P
Michl
Thomas M
TM
Gress
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015815:Cell Adhesion Molecules / Q000008:administration & dosage / Q000494:pharmacology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006820:Hyaluronic Acid / Q000378:metabolism*; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage / Q000494:pharmacology; D051379:Mice; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D015815:Cell Adhesion Molecules; D011994:Recombinant Proteins; D003841:Deoxycytidine; D006820:Hyaluronic Acid; D006821:Hyaluronoglucosaminidase; C066852:hyaluronidase PH-20; D000093542:Gemcitabine